BMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bristol-Myers Squibb Co (BMY) is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. The stock offers a stable dividend yield of 4.2%, a low forward P/E ratio of 9.5, and a strong pipeline of upcoming catalysts in the second half of 2026. Despite some near-term uncertainties, the company's financial performance and valuation make it an attractive long-term value stock.
The stock's MACD histogram is negative at -0.0956, indicating a bearish trend, but it is contracting, suggesting potential stabilization. RSI is neutral at 53.202, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 58.828, with resistance at 60.109 and support at 57.546.
Stable dividend yield of 4.2% and a history of consistent dividend payments.
Low forward P/E ratio of 9.5, making it a value stock.
Upcoming Phase 3 catalysts in H2 2026, including Milvexian and other pipeline developments.
Recent acquisition of Orbital Therapeutics to strengthen its pipeline.
Anticipated decline in revenue from legacy portfolio and patent expirations in
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
MACD and RSI indicators do not show a strong bullish trend.
In Q4 2025, revenue increased by 1.30% YoY to $12.5 billion. Net income surged by 1409.72% YoY to $1.087 billion, and EPS rose by 1225% YoY to $0.53. Gross margin improved to 65.34%, up 8.43% YoY, indicating strong profitability.
Analyst sentiment is mixed but leans positive. Recent ratings include multiple Buy ratings with price targets ranging from $67 to $75, reflecting confidence in the company's pipeline and long-term growth potential. However, some analysts maintain Neutral ratings, citing near-term challenges and reliance on H2 2026 catalysts.
